Movement Alert｜HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors

Market Focus09-18

On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.

On September 16, the company announced that its self-developed Class 1 new drug HS-20197 for injection received clinical trial approval from China's NMPA for the treatment of advanced solid tumors. This adds to a string of favorable developments, including the NMPA's acceptance of the biologics license application for HS-20093, a B7-H3 targeted ADC for small cell lung cancer, and its subsequent inclusion in the priority review program based on positive Phase 3 ARTEMIS-008 data showing a median overall survival of 18.5 months versus 10.3 months for topotecan.

Multiple investment banks have recently reiterated bullish ratings, with Goldman Sachs maintaining a Buy rating and a target price of HK$52.7, JPMorgan maintaining Overweight with a HK$50 target, and UBS rating the stock a Buy. The company reported H1 revenue of RMB 8.3 billion, up 11.7% year-over-year, with innovative drug revenue accounting for 85.4% of total revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185951469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185951469","market":"us","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors","media":"Market Focus","content":"<p><p>On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.</p><p>On September 16, the company announced that its self-developed Class 1 new drug HS-20197 for injection received clinical trial approval from China's NMPA for the treatment of advanced solid tumors. This adds to a string of favorable developments, including the NMPA's acceptance of the biologics license application for HS-20093, a B7-H3 targeted ADC for small cell lung cancer, and its subsequent inclusion in the priority review program based on positive Phase 3 ARTEMIS-008 data showing a median overall survival of 18.5 months versus 10.3 months for topotecan.</p><p>Multiple investment banks have recently reiterated bullish ratings, with Goldman Sachs maintaining a Buy rating and a target price of HK$52.7, JPMorgan maintaining Overweight with a HK$50 target, and UBS rating the stock a Buy. The company reported H1 revenue of RMB 8.3 billion, up 11.7% year-over-year, with innovative drug revenue accounting for 85.4% of total revenue.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.09% in Regular Trading, New Drug HS-20197 Approved for Clinical Trials Targeting Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.</p><p>On September 16, the company announced that its self-developed Class 1 new drug HS-20197 for injection received clinical trial approval from China's NMPA for the treatment of advanced solid tumors. This adds to a string of favorable developments, including the NMPA's acceptance of the biologics license application for HS-20093, a B7-H3 targeted ADC for small cell lung cancer, and its subsequent inclusion in the priority review program based on positive Phase 3 ARTEMIS-008 data showing a median overall survival of 18.5 months versus 10.3 months for topotecan.</p><p>Multiple investment banks have recently reiterated bullish ratings, with Goldman Sachs maintaining a Buy rating and a target price of HK$52.7, JPMorgan maintaining Overweight with a HK$50 target, and UBS rating the stock a Buy. The company reported H1 revenue of RMB 8.3 billion, up 11.7% year-over-year, with innovative drug revenue accounting for 85.4% of total revenue.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1185951469","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185951469","pubTimestamp":1789696904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"异动提醒|豪森制药常规交易大涨3.09%，新药HS-20197获批实体瘤靶向临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On September 18, HANSOH PHARMA rose 3.09% in regular trading, trading at HK$35.4/share, with turnover of HK$61.56 million. The gain comes amid a series of positive catalysts in recent days.On September 16, the company announced that its self-developed Class 1 new drug HS-20197 for injection received clinical trial approval from China's NMPA for the treatment of advanced solid tumors. This adds to a string of favorable developments, including the NMPA's acceptance of the biologics license application for HS-20093, a B7-H3 targeted ADC for small cell lung cancer, and its subsequent inclusion in the priority review program based on positive Phase 3 ARTEMIS-008 data showing a median overall survival of 18.5 months versus 10.3 months for topotecan.Multiple investment banks have recently reiterated bullish ratings, with Goldman Sachs maintaining a Buy rating and a target price of HK$52.7, JPMorgan maintaining Overweight with a HK$50 target, and UBS rating the stock a Buy. The company reported H1 revenue of RMB 8.3 billion, up 11.7% year-over-year, with innovative drug revenue accounting for 85.4% of total revenue.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185951469","isCrawlerRequest":true}